ストックスクリーナーアプリを入手
2.48
1.20%
-0.03
前日終値:
$2.51
開ける：
$2.54
24時間の取引高:
494.33K
Relative Volume:
1.30
時価総額：
$143.60M
収益：
$59.62M
当期純損益:
$8.57M
株価収益率:
20.84
EPS:
0.119
ネットキャッシュフロー:
$-12.62M
1週間 パフォーマンス:
-9.49%
1か月 パフォーマンス:
+1.22%
6か月 パフォーマンス:
+2.06%
1年 パフォーマンス:
+275.76%
1日の値動き範囲:
$2.475
$2.63
1週間の範囲:
$2.471
$2.75
52週間の値動き範囲:
$0.57
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
名前
Spero Therapeutics Inc
セクター
電話
857-242-1600
住所
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.48 | 143.60M | 59.62M | 8.57M | -12.62M | 0.119 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-23 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-09-29 | 開始されました | Evercore ISI | Outperform |
| 2019-11-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-09-09 | 開始されました | Janney | Buy |
| 2018-02-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 開始されました | BofA/Merrill | Neutral |
| 2017-11-27 | 開始されました | Oppenheimer | Outperform |
| 2017-11-27 | 開始されました | Stifel | Buy |
すべてを表示
Spero Therapeutics Inc (SPRO) 最新ニュース
MSN Money - MSN
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
ROSEN, Top Ranked Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO) Stock Volume Spike Alert (Builds on Momentum) 2026-04-20Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics (SPRO) Stock Insider Buying (Market Focus) 2026-04-18Algo Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics Stock Rises Above 50-Day Moving Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics (NASDAQ: SPRO) asks shareholders to double authorized shares to 240M - Stock Titan
Portfolio Shifts: Is Spero Therapeutics Inc stock showing strong momentum2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
MACD Signal: Does Spero Therapeutics Inc have pricing power2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
Can Spero Therapeutics (SPRO) Stock increase dividends | Price at $2.63, Down 5.40%Institutional Buying - Newser
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
Is Spero Therapeutics (SPRO) Stock undervalued by the market | Price at $2.73, Up 0.55%Expert Verified Trades - Newser
Market Overview: Will Spero Therapeutics Inc benefit from seasonality2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
Market Review: What is the PEG ratio of Spero Therapeutics IncInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
Is Spero Therapeutics (SPRO) Stock Reacting to Market | Price at $2.73, Up 2.43%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics Stock Rises Above 50-Day Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Is Spero Therapeutics (SPRO) Stock Growing Now | Price at $2.54, Up 4.32%Viral Momentum Stocks - Newser
Spero Therapeutics Secures Financial Stability Through 2028 () - aktiencheck.de
SPRO Stock Analysis: Spero Therapeutics Inc. Biotech Play at $2.43 Post Minor Daily Dip - Xã Vĩnh Công
Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast - Defense World
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives - Sahm
Spero Therapeutics shares jump over 4% on better-than-expected Q4 print - Investing.com
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - Bitget
Spero Therapeutics earnings beat by $0.73, revenue topped estimates - Investing.com Canada
SPERO THERAPEUTICS ($SPRO) Releases Q4 2025 Earnings - Quiver Quantitative
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS - MarketBeat
Spero Therapeutics Q4 revenue nearly triples, swings to profit - TradingView
Spero Therapeutics 2025 10-K: $66.8M Revenue, $0.15 EPS - TradingView
Spero Therapeutics (NASDAQ: SPRO) turns 2025 profit as tebipenem advances - Stock Titan
BRIEF-Spero Therapeutics Q4 EPS USD 0.56 - TradingView
[10-K] Spero Therapeutics, Inc. Files Annual Report - Stock Titan
Can Spero Therapeutics Inc sustain earnings growth2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - MSN
Analyst Calls: Is Spero Therapeutics Inc stock showing strong momentumWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
If You Invested $1,000 in Spero Therapeuti (SPRO) - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Spero Therapeutics (SPRO.US) will release its earnings report after the market closes on March 26. - 富途牛牛
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Activity Recap: Is Spero Therapeutics Inc stock showing strong momentumPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - The Manila Times
Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday - MarketBeat
Spero Therapeutics Inc 預計每股虧損 55 美分財報前瞻 - TradingView
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Weekly Earnings: What are Spero Therapeutics Incs recent SEC filings showingQuarterly Trade Report & Capital Efficient Trading Techniques - baoquankhu1.vn
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest - MarketBeat
Spero Therapeutics Inc (SPRO) 財務データ
収益
当期純利益
現金流量
EPS
Spero Therapeutics Inc (SPRO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Keutzer Timothy | Chief Operating Officer |
Feb 06 '26 |
Sale |
2.36 |
18,652 |
44,019 |
742,506 |
| Keutzer Timothy | Chief Operating Officer |
Feb 03 '26 |
Sale |
2.14 |
24,224 |
51,839 |
764,629 |
| Keutzer Timothy | Chief Operating Officer |
Feb 02 '26 |
Sale |
2.20 |
18,891 |
41,560 |
788,853 |
| Keutzer Timothy | Chief Operating Officer |
Feb 04 '26 |
Sale |
2.24 |
3,471 |
7,775 |
761,158 |
| Rajavelu Esther | See Remarks |
Feb 02 '26 |
Sale |
2.20 |
18,442 |
40,572 |
1,100,008 |
| Rajavelu Esther | See Remarks |
Nov 07 '25 |
Sale |
2.37 |
40,270 |
95,440 |
869,450 |
| Mahadevia Ankit | Director |
Aug 28 '25 |
Sale |
1.97 |
6,572 |
12,947 |
703,294 |
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
2.45%
大文字化:
|
ボリューム (24 時間):